the ekf central laboratory range includes clinical reagents and centrifuges which are manufactured at premises near san antonio, texas. in 2017 ekf sold more than 22 million tests for the diaspect tm range, and 19 million tests for hemo control and hemopoint® h2 hemo control tm • uses ‘gold standard’ methodology (reagent filled microcuvettes) • data management capability; provides a hematocrit calculation • proven, robust analyser sold worldwide diaspect tm • handheld analyser utilising reagentless methodology • benefits of speed to result (one second), and shelf- life of microcuvettes • connectivity to a mobile phone application now available diaspect hemoglobin t low • tests serum, plasma, aqueous solutions or stored erythrocytes • estimates the degree of hemolysis • results in less than two seconds • reagent-free microcuvettes ultracrit tm • hematocrit analyser using unique ultrasound technology • strong presence in us blood banking sector hematastat ii tm • laboratory hematocrit centrifuge and analyser • processes multiple samples ekf diagnostics holdings plc | annual report 2017 5 1.0 strategic review point-of-care: diabetes care product portfolio ekf’s diabetes care range aims to provide affordable, easy-to-use technology that reduces the costs of long-term healthcare of the diabetic and pre-diabetic population. lactate scout+ has historically been sold into sports medicine, specifically endurance activities such as cross-country skiing, cycling and rowing. during this time it has built a global customer base for its clinical chemistry reagents that can be used on most open-channel analyser platforms. while we are not currently planning further closures, our efforts to improve efficiency and therefore reduce costs continue. operations we have succeeded in our aim for 2017 of driving the existing business and continuing to reduce cost. new and updated products we have concentrated in 2017 on widening the range of regulatory approvals for our existing product ranges. he has also held positions at fisher scientific, trw seat belt systems, maxtor corporation, united technologies carrier and abbott diagnostics gmbh in germany. this risk is minimised by ensuring that a minimum of two individuals manage every relationship with key customers and suppliers. political risk a significant proportion of the group’s revenues are accounted for by agreements in developing countries. the group seeks to mitigate this risk by securing patent registration protection for its products, maintaining confidentiality agreements regarding the group’s know-how and technology, monitoring technological developments and by selecting leading businesses in their respective fields as distribution partners capable of addressing significant competition, should it arise. this report sets out the group policy on directors’ remuneration, including emoluments, benefits and other share-based awards made to each director. we concur with management’s assertion that no further impairment charge is required in respect of goodwill and intangible assets but identified that if management is unable achieve planned results, this could reasonably be expected to give rise to an impairment in the future. the financial statements were approved and authorised for issue by the board on 14 march 2018 and signed on its behalf by: julian baines richard evans chief executive officer finance director and chief operating officer ekf diagnostics holdings plc registered no: 04347937 as at 31 december 2017 ekf diagnostics holdings plc | annual report 2017 33 3.0 financial statements consolidated and company’s statements of cash flows notes group 2017 £’000 group 2016 £’000 company 2017 £’000 company 2016 £’000 cash flow from operating activities cash generated by operations 35 10,118 8,816 4,270 646 interest paid (106) (496) (48) (283) income tax (paid)/received (959) 623 (19) (13) net cash generated by operating activities 9,053 8,943 4,203 350 cash flow from investing activities sale of investments - 250 - 250 purchase of property, plant and equipment (ppe) (1,361) (1,261) (15) (27) purchase of intangibles (852) (663) (65) (56) proceeds from sale of ppe 35 128 211 - - interest received 53 37 - - net cash (used in)/generated by investing activities (2,032) (1,426) (80) 167 cash flow from financing activities proceeds from issuance of ordinary shares 28 - 4,539 - 4,539 share based payments (1,505) - (1,505) - share buy back (241) - (241) - new loans - 5,957 - 3,500 repayments on borrowings (4,458) (12,555) (4,141) (6,000) dividend payment to non-controlling interest (215) (54) - - net cash (used in)/generated by financing activities (6,419) (2,113) (5,887) 2,039 net increase/(decrease) in cash and cash equivalents 602 5,404 (1,764) 2,556 cash and cash equivalents at beginning of year 7,874 2,017 2,567 11 exchange (losses)/gains on cash and cash equivalents (273) 453 (93) - cash and cash equivalents at end of year 23 8,203 7,874 710 2,567 for the year ended 31 december 2017 34 annual report 2017 | ekf diagnostics holdings plc 3.0 financial statements consolidated share capital £’000 share premium account £’000 other reserve £’000 foreign currency reserve £’000 retained earnings £’000 total £’000 non- controlling interest £’000 total equity £’000 at 1 january 2016 4,221 91,276 41 (3,607) (45,438) 46,493 261 46,754 comprehensive income (loss)/profit for the year - - - - (18) (18) 187 169 other comprehensive income currency translation differences - - - 9,216 - 9,216 127 9,343 total comprehensive income/ (expense) - - - 9,216 (18) 9,198 314 9,512 transactions with owners proceeds from shares issued 422 4,117 - - - 4,539 - 4,539 dividends to non-controlling interest - - - - - - (54) (54) share-based payments - - - - 220 220 - 220 total contributions by and distributions to owners 422 4,117 - - 220 4,759 (54) 4,705 at 31 december 2016 and 1 january 2017 4,643 95,393 41 5,609 (45,236) 60,450 521 60,971 comprehensive income profit for the year - - - - 2,715 2,715 225 2,940 other comprehensive income currency translation differences - - - (717) 98 (619) (3) (622) total comprehensive (expense)/ income - - - (717) 2,813 2,096 222 2,318 transactions with owners share cancellation (67) - 67 - (3,121) (3,121) - (3,121) capital reconstruction - (95,393) - - 95,393 - - - dividends to non-controlling interest - - - - - - (215) (215) share-based payments - - - - 545 545 - 545 total contributions by and distributions to owners (67) (95,393) 67 - 92,817 (2,576) (215) (2,791) at 31 december 2017 4,576 - 108 4,892 50,394 59,970 528 60,498 consolidated statement of changes in equity ekf diagnostics holdings plc | annual report 2017 35 3.0 financial statements company’s statement of changes in equity company share capital £’000 share premium £’000 other reserves £’000 retained earnings £’000 total £’000 at 1 january 2016 4,221 91,276 - (40,419) 55,078 comprehensive income loss for the year - - - (5,474) (5,474) total comprehensive income/(expense) - - - (5,474) (5,474) transactions with owners proceeds from shares issued 422 4,117 - - 4,539 share-based payments - - - 220 220 total contributions by and distributions to owners 422 4,117 - 220 4,759 at 31 december 2016 and 1 january 2017 4,643 95,393 - (45,673) 54,363 comprehensive income loss for the year - - - (1,741) (1,741) total comprehensive expense - - - (1,741) (1,741) transactions with owners share cancellation (67) - 67 (3,121) (3,121) capital reconstruction - (95,393) - 95,393 - share-based payments - - - 545 545 total contributions by and distributions to owners (67) (95,393) 67 92,817 (2,576) at 31 december 2017 4,576 - 67 45,403 50,046 36 annual report 2017 | ekf diagnostics holdings plc 3.0 financial statements notes to the financial statements 1. general information ekf diagnostics holdings plc is a company incorporated and domiciled in the united kingdom. (ii) foreign exchange – fair value risk translation exposures that arise on converting the results of overseas subsidiaries are not hedged. where overseas acquisitions are made, it is the group’s policy to arrange any borrowings required in local currency. 523 loushan-guan road, changning district, shanghai, p.r.c.200051 subsequent to 31 december 2017 renalytix ai, inc. was incorporated and registered in the united states of america. on 20 october 2017 the company acquired 5,630,032 ordinary shares which were previously held in escrow at a fair value of 24p per share.